Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?

被引:34
作者
Abedon, Stephen T. [1 ]
Danis-Wlodarczyk, Katarzyna M. [2 ]
Alves, Diana R. [1 ]
机构
[1] Ohio State Univ, Dept Microbiol, Mansfield, OH 44906 USA
[2] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA
关键词
bacteriophage therapy; case study; clinical study; combination therapy; compassionate use; expanded access; BACTERIOPHAGE THERAPY; PSEUDOMONAS-AERUGINOSA; SUSTAINED-RELEASE; ORAL APPLICATION; INFECTION; PRINCIPLES; ENDOLYSINS; EXPERIENCE; HEALTHY; ERADICATION;
D O I
10.3390/ph14111157
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Many bacteriophages are obligate killers of bacteria. That this property could be medically useful was first recognized over one hundred years ago, with 2021 being the 100-year anniversary of the first clinical phage therapy publication. Here we consider modern use of phages in clinical settings. Our aim is to answer one question: do phages serve as effective anti-bacterial infection agents when used clinically? An important emphasis of our analyses is on whether phage therapy-associated anti-bacterial infection efficacy can be reasonably distinguished from that associated with often coadministered antibiotics. We find that about half of 70 human phage treatment reports-published in English thus far in the 2000s-are suggestive of phage-mediated anti-bacterial infection efficacy. Two of these are randomized, double-blinded, infection-treatment studies while 14 of those studies, in our opinion, provide superior evidence of a phage role in observed treatment successes. Roughly three-quarters of these potentially phage-mediated outcomes are based on microbiological as well as clinical results, with the rest based on clinical success. Since many of these phage treatments are of infections for which antibiotic therapy had not been successful, their collective effectiveness is suggestive of a valid utility in employing phages to treat otherwise difficult-to-cure bacterial infections.
引用
收藏
页数:25
相关论文
共 151 条
  • [1] Phage-Encoded Endolysins
    Abdelrahman, Fatma
    Easwaran, Maheswaran
    Daramola, Oluwasegun I.
    Ragab, Samar
    Lynch, Stephanie
    Oduselu, Tolulope J.
    Khan, Fazal Mehmood
    Ayobami, Akomolafe
    Adnan, Fazal
    Torrents, Eduard
    Sanmukh, Swapnil
    El-Shibiny, Ayman
    [J]. ANTIBIOTICS-BASEL, 2021, 10 (02): : 1 - 31
  • [2] Abedon S.T., 2020, BIOFILM PILONIDAL CY, V1, P121
  • [3] Abedon ST, 2015, Bacteriophage, V5, DOI [10.1080/21597081.2015.1020260, DOI 10.1080/21597081.2015.1020260]
  • [4] Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections
    Abedon, Stephen T.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2019, 145 : 18 - 39
  • [5] Abedon ST, 2017, AIMS MICROBIOL, V3, P649, DOI [10.3934/microbio1.2017.3.649, 10.3934/microbiol.2017.3.649]
  • [6] Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent
    Abedon, Stephen T.
    [J]. MICROBIOLOGY SPECTRUM, 2017, 5 (04):
  • [7] Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets?
    Abedon, Stephen T.
    [J]. FEMS MICROBIOLOGY LETTERS, 2016, 363 (03)
  • [8] Abedon Stephen T, 2011, Bacteriophage, V1, P174
  • [9] Abedon Stephen T, 2011, Bacteriophage, V1, P66
  • [10] Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States
    Aslam, Saima
    Lampley, Elizabeth
    Wooten, Darcy
    Karris, Maile
    Benson, Constance
    Strathdee, Steffanie
    Schooley, Robert T.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):